SEngine Precision Medicine Presents Innovative Data on the CLIA Certified PARIS® Test for Oncology Drug Sensitivity and the Future of Functional Precision Medicine at AACR 2020
SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived?tumor-based organoids, today presents data on the predictive value of the PARIS® Test in its poster, “Organoid-based functional test to predict personalized treatment in cholangiocarcinoma” (poster board #818), during the 2020 AACR Virtual Meeting being held June 22-24, 2020.
The PARIS® Test is a CLIA certified functional drug assay using tumor-derived organoids. By compiling assay results, the PARIS® Test generates an actionable report to oncologists as a tool for therapeutic decisions, ranking sensitivity to targeted, endocrine and chemotherapy agents.
Dr. Astrid Margossian, M.D, Ph.D., Chief Medical Officer at SEngine, presents their poster summarizing the strong correlation between genomics,?retrospective treatment outcomes and PARIS® Test drug sensitivity results based on a retrospective analysis of cholangiocarcinoma patients. The poster also highlights encouraging data on positive prospective evidence from three patients who received a PARIS® Test guided treatment, each with good clinical outcome correlation. Cholangiocarcinoma is a rare type of cancer with limited therapeutic options. SEngine has demonstrated utility of the PARIS® Test as a tool for oncologists to design innovative therapeutic strategies for cholangiocarcinoma patients.
In addition to SEngine’s poster presentation, scientific leadership at the company lead the AACR Education Session Functional Precision Medicine: Techniques, Uses and Challenges on June 23, 2020. Christopher Kemp, Ph.D., Scientific Director at SEngine Precision Medicine and full member of the Fred Hutchinson Cancer Research Center, chairs the education session. Chif Executive Officer Dr. Carla Grandori, M.D., Ph.D., presents on the strong predictive value of the PARIS® Test and provides key takeaways from five years running SEngine’s CLIA certified organoid-based drug sensitivity assay.
Details related to the poster presentation are as follows:
Details related to the education session are as follows:
About the PARIS® Test
About SEngine Precision Medicine
Protecting Critical Infrastructure with Epic Security
Session Details TBA